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Background: Dengue is a serious arboviral disease currently with no effective antiviral therapy or approved vaccine
available. Therefore, finding the effective compound against dengue virus (DENV) replication is very important.
Among the natural compounds, bioflavonoids derived mainly from plants are of interest because of their biological
and medicinal benefits.
Methods: In the present study, antiviral activity of a bioflavonoid, baicalein, was evaluated against different stages
of dengue virus type 2 (DENV-2) replication in Vero cells using focus forming unit reduction assay and quantitative
RT-PCR.
Results: Baicalein inhibited DENV-2 replication in Vero cells with IC50= 6.46 μg/mL and SI= 17.8 when added after
adsorption to the cells. The IC50 against DENV-2 was 5.39 μg/mL and SI= 21.3 when cells were treated 5 hours
before virus infection and continuously up to 4 days post infection. Baicalein exhibited direct virucidal effect against
DENV-2 with IC 50= 1.55 μg/mL and showed anti-adsorption effect with IC50 = 7.14 μg/mL.
Conclusions: Findings presented here suggest that baicalein exerts potent antiviral activity against DENV. Baicalein
possesses direct virucidal activity against DENV besides its effects against dengue virus adsorption and intracellular
replication of DENV-2. Baicalein, hence, should be considered for in vivo evaluation in the development of an
effective antiviral compound against DENV.
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Dengue is among the most widespread mosquito-borne
diseases. It is endemic in many tropical and sub-tropical
parts of the world and is rapidly spreading to other
countries where the mosquito vectors, Aedes aegypti and
Aedes albopictus are found [1,2]. Dengue infection is
caused by dengue virus (DENV), a flavivirus belonging
to the Flaviviridae family. There are four distinct DENV
genotypes, DENV-1, DENV-2, DENV-3 and DENV-4.
All four genotypes can cause a wide range of illnesses
ranging from a mild febrile infection, self limited dengue
fever (DF) to severe dengue hemorrhagic fever (DHF)
and dengue shock syndrome (DSS). Dengue has resulted
in many deaths with an annual estimate of 50 million
deaths worldwide [3]. Currently there is no licensed* Correspondence: sazaly@um.edu.my
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reproduction in any medium, provided the orvaccine for dengue and the development of vaccine has
been very challenging due to the complexity of immune
responses against dengue. A number of reports have
suggested that there is a direct correlation between the
amount of DENV present in the blood during the
viremic phase and the severity of dengue [4]. Therefore,
viral load reduction due to using effective antiviral may
perhaps decrease the chance of severe dengue complica-
tions, DHF and DSS. There are a number of plant-derived
compounds with potential antiviral activity [5-10]. These
include, bioflavonoids, which are polyphenolic plant deri-
vatives with many patented biological benefits including as
antivirals [11-13]. We have previously reported that the
flavonoids fisetin and quercetin exhibited anti-dengue
virus activities [14,15]. Baicalein is a flavone (C15H10O5)
commonly isolated from the root of Scutellaria baicalensis.
Scutellaria baicalensis is one of the traditional Chinese me-
dicinal herbs and is among the Labiatae family. Its roots
have been used as medication for some diseases such astd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and hyperlipidemia. Here we examined the anti-dengue
virus properties of baicalein.
Methods
Flavonoid
Baicalein was purchased from Indofine Chemical Company
(Indofine, NJ, USA) and the stock solution (20 mg/mL) was
prepared in dimethyl sulfoxide (DMSO) (Sigma-Aldrich,
St. Louis, MO, USA). Stock solution was aliquoted and
stored at −20°C until needed. Stock solution was diluted
with Eagle’s Minimum Essential Medium (EMEM, Gibco,
NY, USA) and was filtered through a syringe filter with
0.2 μm pore size (Millipore, MA, USA) at the time of
experiment.
Cells and virus
C6/36 mosquito cell line and the African green monkey
kidney cells (Vero) from American Type Culture Collec-
tion (ATCC) were used in this study. Both cell lines were
propagated and maintained in EMEM supplemented
with 10% fetal bovine serum (FBS) (Gibco, NY, USA).
Vero and C6/36 cells were incubated at 37°C and 28°C,
respectively. Dengue virus type-2 (DENV-2) New Guinea
C strain (NGC) was propagated in C6/36 cells and har-
vested after cytopathic effects (CPE) were observed on
day seven post infection. Virus stock titer was deter-
mined by foci forming assay (FFA) as previously
described [14] and then aliquoted and stored at −70°C.
During the time of virus propagation, the FBS concen-
tration of the cell culture medium was reduced to 2%.
Cytotoxicity assay
In this study, cytotoxicity of the baicalein was deter-
mined using MTT assay as previously described [16].
Briefly, monolayer of Vero cells were seeded in 96-well
microplates and treated with different concentrations of
baicalein in triplicates. Cells were treated for four days
at 37°C, under similar condition and duration used for
antiviral activity assay. At the end of the incubation
period, 15 μl of MTT solution (Promega, WI, USA) was
added to each well. The microplate was kept at 37°C for
4 hours followed by adding 100 μl of the solubilization
solution/stop mix to each well. The optical density (OD)
of the wells were measured at 570 using 96-well plate
reader (TECAN, Mannendorf, Switzerland) and the
dose–response curve was plotted using GraphPad Prism
5 (GraphPad Software Inc., San Diego, CA).Focus Formation Unit Reduction Assay (FFURA)
Antiviral activity of baicalein was determined by measur-
ing the reduction in the number of viral foci. Briefly,
confluent monolayers of Vero cells were prepared in 24wells cell culture microplate. The infected cells were
overlaid with 1.5% CMC containing EMEM with 2%
FBS. Viral foci were visualized using peroxidase-based
foci staining assay [17] four days post infection. The
number of DENV-2 foci was counted using stereomicro-
scope and the titer of virus was expressed as Foci-
Forming-Unit (FFU). The base-line for negative control
(untreated infected cells) was the mean of the viral foci
number ± SD in untreated wells. Then the percentage of
foci reduction (RF %) compared to negative control was
calculated as follows: RF(%) = (C-T) × 100/C.
Where, C is the mean of the number of foci for nega-
tive control well (without compound) and T is the mean
of the number of foci in treated wells. The data from re-
duction in number of viral foci were verified and con-
firmed by quantitative RT-PCR (qRT-PCR).
Dengue virus quantitative RT-PCR
DENV-2 RNA copy number was measured using the
quantitative RT-PCR method as previously described
with some modifications [18]. Briefly, intracellular and
extracellular DENV-2 RNA was harvested from the
DENV infected Vero cells. Viral RNA was extracted
using RNA extraction kits (Qiagen RNA extraction kit
and Qiagen RNeasy kit). The real-time RT-PCR assay
was performed by adding 1 μl of extracted DENV RNA
to the SensiMix SYBR green mixture (Quantace,
Watford, United Kingdom) which contained 7.4 μl
ddH2O, 10 μl 2X SensiMix One-Step, 0.4 μl 50X SYBR
Green solution, 10 units of RNAse Inhibitor, 50 pmol of
forward (DNF) and also reverse (D2R) primers [19]. All
samples were assayed in triplicate. The amplification was
performed using the DNA Engine Opticon system (MJ
Research/Bio-Rad, Hercules, CA) with the following
thermal cycling conditions: reverse transcription at 50°C
for 30 min, initial denaturation at 95°C for 10 min, fol-
lowed by 45 cycles of 95°C for 15 sec, 59°C for 30 sec
and 72°C for 30 sec. Melting curve analysis was subse-
quently performed at temperature from 60°C to 98°C to
verify the assay specificity. The absolute quantities of
viral RNA in the samples were measured with a standard
curve that was generated with a 5-fold serially diluted
viral RNA extracted from DENV-2 virus inoculums of
known titer. The standard curve consisted of 7 points of
concentration ranging from 107 to 103 FFU/ml. Each
concentration was assayed in triplicate (Additional file 1:
Figure S1).
Prophylactic and continuous treatment studies
Anti-viral activity of baicalein was examined in Vero
cells using different concentrations at various time point
of virus infection. Vero cells were used as these cells
allowed for efficient DENV replication in contrast to
human cells which were less permissive in vitro. To
Figure 1 Cytotoxicity of baicalein on Vero cells. MTT assay was
used to evaluate the cytotoxicity of the flavonoid. All experiments
were conducted in triplicates.
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lein, Vero cells were pre-treated with baicalein for
5 hours prior to infection. The treatment media were
removed and the treated cells were washed twice with
PBS. The cells were inoculated with 200 FFU of DENV-2
and incubated at 37°C for 1 h for virus adsorption. After
4 days of infection, antiviral activity was determined by re-
duction in foci numbers as described above. In separate
experiment, cells were pre-treated with baicalein for
5 hours prior to infection and the compound was continu-
ously present in the cell culture for 5 days until termin-
ation of the experiment.
Anti-adsorption activity
The activity of baicalein against adsorption of DENV-2
to the Vero cells was measured by inoculating the con-
fluent Vero monolayers in 24-wells cell culture micro-
plate with 200 FFU of DENV-2 in the presence or
absence of different concentrations of baicalein and
incubated at 37°C for 1 hour for virus adsorption. Then
the cells were washed by sterile PBS twice and overlayed
with 1.5% CMC containing EMEM with 2% FBS. After
4 days of experiment, anti-adsorption activity of baica-
lein was determined by reduction in foci numbers as
described above.
Post-adsorption antiviral activity
Antiviral activity of baicalein against intracellular repli-
cation of DENV-2 was performed by treating Vero cells
with baicalein after adsorption with 200 FFU of virus for
1 hour at 37°C and following washing with PBS to elim-
inate the unabsorbed viruses. Cells were treated with dif-
ferent concentrations of baicalein for 4 days. Antiviral
activity was determined by viral foci reduction assay and
qRT-PCR.
Direct virucidal assay
Extracellular anti-dengue activity of baicalein was inves-
tigated by incubating DENV-2 suspension containing
200 FFU with equal volume of the different concentra-
tions of baicalein for 1 h at 37°C. Then, Vero cells were
infected with the treated viral suspension for 1 h at 37°C.
Cells were washed with PBS to remove the unabsorbed
viruses. Then the microplate was incubated at 37°C for
4 days. Antiviral activity was determined by the reduction
in number of viral foci and qRT-PCR.
Statistical analysis
The cytotoxic concentration of baicalein that reduced
cells survival by 50% (CC50) and the inhibitory concen-
tration the reduced the number of foci by 50% (IC50)
were determined using GraphPad Prism for Windows,
version 5 (Graph Pad Software Inc., San Diego, CA,
2005). Selectivity Index value (SI) was determined as theratio of CC50 to IC50 for that compound as previously
described [14].
Results
Cytotoxicity of baicalein
Cytotoxicity of baicalein on Vero cells were evaluated
using the MTT assay. The related CC50 was then calcu-
lated using Graph Pad Prism for Windows, version 5
(GraphPad Software Inc., San Diego, CA). Our results
suggest that baicalein when added to Vero cells exhibited
cytotoxic effects with CC50=109 μg/mL (Figure 1). More
than 75% of Vero cells were viable in the presence of
12.5 ug/mL of baicalein which is important for our anti-
viral assays in next step. The vehicle control, 1% DMSO,
did not show any cytotoxic effects against Vero cells.
Antiviral assays with baicalein against DENV-2
Foci forming unit reduction assay was used to evaluate the
in vitro anti-dengue virus activities of baicalein (Figure 2).
Baicalein was added at the different phases of viral infec-
tion: i) pre-treatment for 5 hours prior to infection for its
prophylactic activity, ii) treatment during virus adsorption
time iii) treatment for 4 days post-adsorption, iv) continu-
ous treatment from 5 h before infection and up to 5 days
of infection and v) directly to cell free virus suspension to
examine its direct virucidal effect.
Pre-treatment of Vero cells with 12.5 μg/mL decreased
formation of virus foci to below 30% (Figure 3A). The
base-line value for the negative control of prophylactic
treatment was 76.6 ± 4 based on the mean of viral foci in
un-treated wells. However, using the negative control
base-line value the percentage of the foci reduction (RF %)
was calculated and used for plotting. The level of DENV-2
RNA was reduced by 32% ± 0.8 at 12.5 μg/mL of baicalein
when compared to the non treated DENV infected cells
(Figure 3B). Baicalein when added simultaneously with the
A B
C D
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Figure 2 DENV-2 foci in Vero cells treated with or without baicalein. prophylactic treatment with 12.5 μg/ml of baicalein (A) or without
baicalein (B); during adsorption with 12.5 μg/ml of baicalein (C) or without baicalein (D); after virus adsorption with 12.5 μg/ml of baicalein (E) or
without baicalein (F); direct virucidal activity with 12.5 μg/ml of baicalein (G) or without baicalein (H). Foci were detected using dengue
hyperimmune sera after 4 days of incubation.
Zandi et al. BMC Complementary and Alternative Medicine 2012, 12:214 Page 4 of 9
http://www.biomedcentral.com/1472-6882/12/214virus showed anti-adsorption activity against DENV-2
with IC50 = 7.14 μg/mL (Figure 4A) and with SI value of
16.1. The base-line mean value of viral foci in the negative
control (un-treated wells) of anti-adsorption activity was
78.6 ± 2. Production of viral RNA decreased by 75% ± 3 in
the presence of 12.5 μg/mL baicalein during the viral ad-
sorption period (Figure 4B). In post adsorption assay,baicalein exhibited potent antiviral activity against DENV-2
with IC50 = 6.46 μg/mL (Figure 5A). The base-line value
for the negative control of post-adsorption treatment was
69.6 ± 3.5 based on the mean of viral foci number in un-
treated wells. The copy number of viral RNA decreased by
62.9% ± 3 when the infected cells were treated with
12.5 μg/mL (Figure 5B).
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Figure 3 Prophylactic effects of baicalein against DENV-2 replication. Foci forming unit reduction assay was used to evaluate the
prophylactic activity of the baicalein (A). and the DENV-2 RNA copies were quantified using qRT-PCR (B). All experiments were conducted in
triplicates. The percentages of foci reduction (%RF) and RNA copy number reduction were obtained by comparing against the controls
maintained in parallel.
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of cells from 5 h before virus infection up to 4 days post
infection was 5.39 μg/mL and its SI value was 21.3
(Figure 6A). The mean of viral foci number in negative
control wells was 71 ± 3.5 as a base-line for the foci re-
duction percentage calculation. Quantitative RT-PCR
results showed that 12.5 μg/mL of baicalein decreased0 20 40 60
0
20
40
60
80
100
Concentration (µg/mL)
(A)
RF
%
Figure 4 Effects of baicalein against DENV-2 host cell adsorption. Foc
adsorption activity of baicalein against dengue virus (A) the respective DEN
were conducted in triplicates. The percentages of foci reduction (%RF) and
controls maintained in parallel.the DENV-2 RNA production 69.2 ± 1.6 but at 25 μg/mL
of baicalein viral RNA level production decreased more
than 90% (Figure 6B).
Results from direct virucidal activity assessment of bai-
calein showed that baicalein exhibited a potent extracel-
lular anti-DENV-2 activity with IC50 = 1.55 μg/mL
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Figure 5 Antiviral activity of baicalein against DENV-2 intracellular replication. Foci forming unit reduction assay was used to evaluate the
anti-dengue activity of baicalein after virus adsorption to the Vero cells (A) and the respective DENV-2 RNA copies were quantified using qRT-PCR
(B). All experiments were conducted in triplicates. The percentages of foci reduction (%RF) and RNA copy number reduction were obtained by
comparing against the controls maintained in parallel.
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mean of viral foci number in un-treated wells. Similarly,
qRT-PCR analysis showed that 12.5 μg/mL of baicalein
decreased the DENV-2 RNA production 99.2% ± 0.4
(Figure 7B).
Discussion
Flavonoids in general are natural compounds that are
ubiquitously found in plants. They are described as less0 20 40 60
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Figure 6 Anti-dengue effect of continuous treatment with baicalein. F
anti-dengue virus activities of the baicalein (A). The respective DENV-2 RNA
foci reduction (%RF) and RNA copy number reduction were obtained by cotoxic in comparison to other plant compounds such as
the alkaloids and therefore, can be consumed in higher
amount. Many studies have shown that flavonoids can
have beneficial effects on human health and these ranges
from anticancer to antimicrobial effects [20,21]. Several
studies have also shown that flavonoids exerted antiviral
activities against a number of common viruses including
hepatitis B, herpes simplex viruses, human cytomegalo-
virus and few others [22-25]. There are also reports of0.0
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oci forming unit reduction assay was used to evaluate the in vitro
copy number was quantified using qRT-PCR (B). The percentages of
mparing against untreated controls maintained in parallel.
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Figure 7 Direct virucidal activity of baicalein against DENV-2. Foci forming unit reduction assay was used to determine the direct anti-
dengue virus activity of the baicalein. Baicalein was added directly to virus inoculum prior to infecting cells (A) and the respective DENV-2 RNA
copies were quantified using qRT-PCR (B). All experiments were conducted in triplicates. The percentages of foci reduction (%RF) and RNA copy
number reduction were obtained by comparing against the controls maintained in parallel.
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group of flavonoids that include compounds such as
wogonin, apigenin, luteolin and baicalein [5,26,27]. A
number of flavonoids have also been reported to exhibit
significant anti-dengue properties [28-30]. More re-
cently, we showed that flavones, more exactly, flavonols,
fisetin and quercetin exhibited significant anti-dengue
virus activities in vitro in contrast to hesperetin, narin-
genin, daidzein, naringin and rutin which showed no or
only limited activities against DENV replication [14,15].
Baicalein is a flavone and the main natural resource for
this compound is the roots of Scutellaria baicalensis a
traditional Chinese medicine with different biological ac-
tivities including antiviral activity [31]. Indeed, it has
been reported that a flavone from the roots of S.baicalensis
exhibited significant antiviral activity against influenza
viruses after virus adsorption to the susceptible cell line
[32]. Here, we demonstrated that another flavonoid,
namely, baicalein exhibits significant inhibitory activity
against DENV-2 replication in Vero cells. It is the most
potent flavonoid against DENV identified thus far in com-
parison to fisetin and quercetin. Baicalein similar to other
flavones share common 2-phenylchromen-4-one (2-phenyl-
1-benzopyran-4-one) backbone except for the additional tri
hydroxyl on the flavone (5,6,7-Trihydroxy-2-phenyl-
chromen-4-one or 5,6,7-trihydroxyflavone).
Results from our study suggest that baicalein exhibits
potent in vitro antiviral activity against all stages of the
DENV-2 replication cycle such as adsorption stage(SI = 16.1) and intracellular virus replication (SI = 17.8).
In addition, baicalein showed highly potent direct viruci-
dal activity (SI = 74.3). Its prophylactic activity against
DENV-2 replication was also observed, albeit weaker
(SI = 1.06). These observations suggest that one of the
possible mechanisms for baicalein extracellular and
intracellular activities against DENV-2 could be attribu-
ted to its ability to bind and/or to inactivate important
structural and/or non structural protein(s) of DENV-2.
Such inhibitory mechanism was previously reported for
pinostrobin which inhibits dengue virus NS3 protein
[29]. Baicalein has also been reported to bind to HIV-1
integrase [33]. Furthermore, increasing SI values from
17.8 to 21.3 was observed when baicalein was used to
treat cells 5 h before infection and continuously for
4 days post infection. In some studies, activity of several
flavonoids against cellular RNA polymerases and forma-
tion of the complex with RNA were reported [34,35].
Therefore, it is possible that baicalein inhibits DENV
replication by interfering with DENV-2 RNA polymerase
and/or bind to the viral RNA which should be noted for
future investigations. Results from qRT-PCR supported
the findings from viral foci reduction but the inhibition
of RNA production was more significant than inhibition
of DENV-2 foci formation. In all our experiments, we
showed that 0.5% of DMSO the solvent need initially to
dissolve bioflavonoid, did not exhibit any antiviral activ-
ity against DENV-2 and this eliminated any probable
antiviral activity from DMSO.
(A) (B)
Figure 8 Chemical structure of flavone (A) and baicalein (B).
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butes to the inhibitory effects is not presently known. In
an earlier study however, we showed that flavone signifi-
cantly enhances DENV replication in Vero cells [36].
The differences in structure between these two com-
pounds lies in the presence of three hydroxyl group in
baicalein (Figure 8B) in comparison to the flavone
(Figure 8A), suggesting the potential importance of the
hydroxyl groups. This possibility is supported by the
findings of a previous study that has demonstrated
the presence and the positions of hydroxyl group in baica-
lein is crucial for its activity against HIV-1 reverses tran-
scriptase enzyme in comparison to flavone [37].Conclusions
In summary, our study demonstrated that baicalein
exhibited potent anti-dengue activity in vitro, in particu-
lar its virucidal activity against extracellular DENVs.
Results from this study warrant future in vivo anti-viral,
toxicity and pharmacokinetic studies as part of the de-
velopmental process for development of baicalein as po-
tential anti-dengue therapeutic.Additional file
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